SuperHERONCT07895511
A Study of Skipping Radiation Therapy in People With Breast Cancer
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Ipsilateral breast recurrence/IBR rate
Timeframe: 5 years
Arms and interventions
HER2-positive Breast CancerExperimental
Participants have HER2-positive Breast Cancer
Drugs: HER2-targeted therapy, Tamoxifen
Radiation: No Radiation Therapy
Sites
7 sites in 1 country